- Home
- KPRX vs MRM Comparison
KPRX vs MRM Comparison
Compare KPRX & MRM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KPRX
- MRM
- Stock Information
- Founded
- KPRX 1998
- MRM 2000
- Country
- KPRX United States
- MRM Japan
- Employees
- KPRX N/A
- MRM N/A
- Industry
- KPRX Biotechnology: In Vitro & In Vivo Diagnostic Substances
- MRM Other Consumer Services
- Sector
- KPRX Health Care
- MRM Consumer Discretionary
- Exchange
- KPRX Nasdaq
- MRM Nasdaq
- Market Cap
- KPRX 11.0M
- MRM 12.2M
- IPO Year
- KPRX N/A
- MRM 2020
- Fundamental
- Price
- KPRX $3.18
- MRM $2.64
- Analyst Decision
- KPRX Strong Buy
- MRM
- Analyst Count
- KPRX 1
- MRM 0
- Target Price
- KPRX $10.00
- MRM N/A
- AVG Volume (30 Days)
- KPRX 45.3K
- MRM 11.0K
- Earning Date
- KPRX 11-19-2024
- MRM 12-30-2022
- Dividend Yield
- KPRX N/A
- MRM N/A
- EPS Growth
- KPRX N/A
- MRM N/A
- EPS
- KPRX 1.53
- MRM 0.16
- Revenue
- KPRX $16,020,000.00
- MRM $48,438,179.00
- Revenue This Year
- KPRX N/A
- MRM N/A
- Revenue Next Year
- KPRX N/A
- MRM N/A
- P/E Ratio
- KPRX $2.29
- MRM $16.64
- Revenue Growth
- KPRX N/A
- MRM N/A
- 52 Week Low
- KPRX $3.00
- MRM $2.27
- 52 Week High
- KPRX $8.98
- MRM $8.39
- Technical
- Relative Strength Index (RSI)
- KPRX 43.73
- MRM 44.19
- Support Level
- KPRX $3.47
- MRM $2.51
- Resistance Level
- KPRX $3.75
- MRM $2.81
- Average True Range (ATR)
- KPRX 0.22
- MRM 0.26
- MACD
- KPRX -0.03
- MRM 0.00
- Stochastic Oscillator
- KPRX 0.00
- MRM 40.00
About KPRX Kiora Pharmaceuticals Inc.
Kiora Pharmaceuticals Inc is a clinical-stage biotechnology company developing and commercializing products for the treatment of orphan retinal diseases. As part of its development, KIO-301 is being studied for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. It is a molecular photoswitch that has the potential to restore vision in patients with inherited and/or age-related retinal degeneration. KIO-104 is being developed for the treatment of posterior non-infectious uveitis. It is a next-generation, non-steroidal, immuno-modulatory, and small-molecule inhibitor of dihydroorotate dehydrogenase.
About MRM MEDIROM Healthcare Technologies Inc.
MEDIROM Healthcare Technologies Inc provides health services. The company is a franchiser and operator of healthcare salons and operates in segments namely Relaxation Salon, Digital Preventative Healthcare, and Luxury Beauty Segment. The company generates a majority of its revenue from the Relaxation Salon business segment. Geographically, the company generates a maximum share of its revenue from Japan.